SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
SAN FRANCISCO, March 06, 2017 -- Hagens Berman Sobol Shapiro LLP reminds investors in PixarBio Corporation (Other OTC:PXRB) of the March 27, 2017 Lead Plaintiff deadline in the pending securities class action.
If you purchased PXRB securities (1) pursuant to PixarBio’s private placement that closed on October 30, 2016 or (2) on the open market between October 30, 2016 and January 20, 2017 (the “Class Period”) and suffered over $25,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/PXRB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On January 3, 2017, PixarBio CEO Frank Reynolds disclosed the Company’s intent to acquire InVivo Therapeutics Holdings Corp. In response, InVivo stated it had never been involved in negotiations with PixarBio and rejected the offer.
Then, on January 23, 2017, the SEC froze trading of PixarBio shares and stated, “the market for the security appears to reflect manipulative or deceptive activities.” Hagens Berman continues to investigate the SEC’s findings.
On February 8, 2017, the Company announced the resignation of Steven J. Chartier, its Chief Operating Officer and former VP of Regulatory Affairs. Mr. Chartier had been PixarBio’s COO for less than 2 months.
“We’re focused on the SEC’s ultimate determination of the matters warranting the trading halt and the damage inflicted on investors,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding PixarBio should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
